Quantcast

Prescient Medical, Inc. CEO Patricia Scheller to Speak at ‘The Value of Innovation in Health Care,’ a Galen Institute Conference

December 7, 2009

DOYLESTOWN, Pa., Dec. 7 /PRNewswire/ — Patricia Scheller, CEO of Prescient Medical, Inc., will be among the speakers at the Galen Institute’s “The Value of Innovation in Health Care” conference. The conference will take place on Wednesday, December 9th in Washington DC at the Columbus Club at Union Station.

The Galen Institute is a non-profit public policy research organization focusing on health and tax policy.

“I’m very pleased to be part of the Galen Institute’s conference,” said Ms. Scheller. “As the debate on health care reform continues, there appears to be bipartisan agreement that continued innovation in medical research and the development of pioneering medical technology is critical. The US has historically led the world in advancing medical progress and the policy initiatives being discussed have the potential to profoundly impact our future position. The Galen Institute’s conference offers a wonderful opportunity to provide input to lawmakers on how their policies can promote innovation.”

The event unites policy experts, elected officials, and leaders in a number of health care-related industries to discuss the effects of health care reform on innovation. Prescient Medical has developed two breakthrough interventional cardiology solutions: the vProtect(TM) Luminal Shield and the vPredict(TM) Optical Catheter System.

The vProtect(TM) Luminal Shield is a novel self-expanding coronary stent-like Shield that received CE Mark certification in August, 2009, allowing it to be marketed in Europe for improving coronary artery luminal diameter in patients with symptomatic ischemic heart disease. The Shield was recently honored with Frost & Sullivan’s 2009 North American Product Innovation of the Year Award. Designed specifically to minimize arterial injury and its consequences, the Shield is ideal for treating softer plaques, such as those that are typically associated with heart attacks.

The vPredict(TM) Optical Catheter System is being developed for the detection and characterization of soft plaque. Its technology platform is based on Raman spectroscopy, a highly sensitive technique proven in numerous non-clinical applications. The vPredict(TM) System detects clinically important compounds, including cholesterols, in the vessel wall and plaque. The goal of the vPredict(TM) System is to provide physicians with information to identify patients at risk for a heart attack and treat them proactively.

For more information on Prescient Medical or its products, please contact Ilana Odess, General Manager of Prescient Medical, at: iodess@pmivp.com.

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. The company is the recipient of the 2009 Frost and Sullivan Award for Product Innovation of the Year Award for vProtect(TM) Luminal Shield. For more information about Prescient Medical and its products, please visit www.prescientmedical.com.

SOURCE Prescient Medical, Inc.


Source: newswire



comments powered by Disqus